Posted from: Friday, March 03, 2017 - 04:57 PM - Present

Opdivo Gains New Indication

February 2, 2017 – The U.S.FDA approved Bristol-Myers Squibb’s Opdivo® (nivolumab),  indicated for treating locally advanced or metastatic urothelial carcinoma (mUC) that has progressed either during or after platinum-containing chemotherapy. Opdivo may also be used within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. mUC is a form of bladder cancer that affects about 70,000 Americans a year, and more than one-half of patients experience a relapse after treatment. To treat mUC recurrence, the recommended dose of Opdivo is 240mg infused intravenously (IV) once every two weeks until the patient no longer responds or no longer tolerates side effects. Opdivo is a programmed death receptor-1 (PD-1) inhibitor, and as an immuno-oncology agent, it helps the body’s immune system attack cancer cells. Since its initial U.S. approval to treat metastatic melanoma in December 2014, Opdivo has been approved, either alone or in combination with other oncology drugs, to treat several other cancer types, including metastatic non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Monday, September 16, 2019 - 08:11 AM.